The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Recap by typeshit. Full story at Competitive Enterprise Institute.
Maria David Patten alleges Novo hid NAION risks; her case joins the federal MDL before Judge Karen Marston in Pennsylvania, where bellwether trials are expected.
HHS now lets pharmacies compound BPC-157, TB-500 and four others, but BoxingInsider notes all six remain on WADA's banned list for licensed boxers.
Politico looks at the warning signs around Health Secretary Kennedy's move to let six peptides that lack FDA approval reach the US market.
Per @pamelajeannoble, the letter flags contamination risks, manufacturing conditions and compounded copies resembling approved drugs.
A post-hoc REDEFINE 1 analysis in 2,309 women showed 25.0% average weight loss on CagriSema at 68 weeks, assuming full adherence. A judge also denied Novo's bid to block Lilly ads.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
Loading…